<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070887</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH 2013-0276</org_study_id>
    <nct_id>NCT02070887</nct_id>
  </id_info>
  <brief_title>Inhibiting COMT in Parkinson's Disease</brief_title>
  <official_title>Inhibiting COMT in Parkinson's Disease A Monocenter, Observational, Rater-blinded Trial of Entacapone in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Baumann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this observational study is to investigate the impact of COMT inhibition&#xD;
      on homocysteine metabolism, vascular physiology and correlates of neurodegeneration in PD&#xD;
      patients with certain COMT genotype. It is designed to evaluate effect size of Hcy lowering&#xD;
      to secondary outcome parameters. Assessment of outcome parameters will be rater-blinded or&#xD;
      computer-based.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum level of homocysteine</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Entacapone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No Entacapone</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary movement disorder clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 60 - 75 years,&#xD;
&#xD;
          -  Caucasian ethnicity,&#xD;
&#xD;
          -  diagnosed PD by UK brain bank criteria,&#xD;
&#xD;
          -  Hoehn &amp; Yahr scale 2 - 3,&#xD;
&#xD;
          -  fertile females have to use contraception&#xD;
&#xD;
          -  Group 1: medication with Stalevo® (L-DOPA/DDI + Entacapone)&#xD;
&#xD;
          -  Group 2: medication with Madopar® or Sinemet® (L-DOPA/DDI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  methotrexate therapy during the last 12 months,&#xD;
&#xD;
          -  treatment with Tolcapone&#xD;
&#xD;
          -  vitamin B6, B12 and/or folic acid supplementation during last 6 months,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  intention to become pregnant during the course of the study,&#xD;
&#xD;
          -  breast feeding,&#xD;
&#xD;
          -  other clinically relevant concomitant disease states by discretion of the investigator&#xD;
&#xD;
          -  known or suspected non-compliance, drug or alcohol abuse,&#xD;
&#xD;
          -  inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia or confusional state of the subject,&#xD;
&#xD;
          -  participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study,&#xD;
&#xD;
          -  enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Baumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Neurology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Christian Baumann</investigator_full_name>
    <investigator_title>Professor dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

